Eisai Co., Ltd.
General ticker "ESALF" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $8.4B (TTM average)
Eisai Co., Ltd. does not follow the US Stock Market performance with the rate: -15.3%.
Estimated limits based on current volatility of 0.2%: low 24.89$, high 25.00$
Factors to consider:
- Company pays dividends (annually): last record date 2026-03-31, amount 0.50$ (Y2.00%)
- Earnings for 12 months up through Q4 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-03-31 to 2027-03-31
- 2025-03-31 to 2026-03-31 estimated range: [17.60$, 35.88$]
- 2026-03-31 to 2027-03-31 estimated range: [18.86$, 37.17$]
Financial Metrics affecting the ESALF estimates:
- Positive: with PPE of 0.4 at the end of fiscal year the price was neutral
- Positive: -5.34 < Operating profit margin, % of 6.89
- Negative: negative Industry operating cash flow (median)
- Negative: negative Industry operating income (median)
- Negative: Investing cash flow per share per price, % of -0.81 <= -0.60
- Negative: 0.01 < Interest expense per share per price, % of 0.28
- Negative: Inventory ratio change, % of 2.42 > 0.80
- Positive: Industry inventory ratio change (median), % of -1.18 <= -0.15
- Positive: 1.77 < Return on assets ratio (scaled to [-100,100]) of 3.24
- Positive: -0.03 < Operating cash flow per share per price, % of 2.42
Short-term ESALF quotes
Long-term ESALF plot with estimates
Financial data
| YTD | 2023-03-31 | 2024-03-31 | 2025-03-31 |
|---|---|---|---|
| Operating Revenue | ¥744,402.00MM | ¥741,751.00MM | ¥789,400.00MM |
| Operating Expenses | ¥704,362.00MM | ¥688,343.00MM | ¥735,022.00MM |
| Operating Income | ¥40,040.00MM | ¥53,408.00MM | ¥54,378.00MM |
| Non-Operating Income | ¥4,972.00MM | ¥8,415.00MM | ¥6,687.00MM |
| Interest Expense | ¥2,266.00MM | ¥2,388.00MM | ¥3,519.00MM |
| R&D Expense | ¥156,691.00MM | ¥169,021.00MM | ¥171,633.00MM |
| Income(Loss) | ¥45,012.00MM | ¥61,823.00MM | ¥61,065.00MM |
| Taxes | ¥-11,824.00MM | ¥18,040.00MM | ¥13,007.00MM |
| Net Income(Loss)* | ¥55,432.00MM | ¥42,407.00MM | ¥46,433.00MM |
| Stockholders Equity | ¥799,959.00MM | ¥875,614.00MM | ¥841,417.00MM |
| Inventory | ¥140,417.00MM | ¥174,651.00MM | ¥215,905.00MM |
| Assets | ¥1,263,350.00MM | ¥1,393,799.00MM | ¥1,386,547.00MM |
| Operating Cash Flow | ¥-1,772.00MM | ¥55,993.00MM | ¥30,117.00MM |
| Capital expenditure | ¥34,559.00MM | ¥24,823.00MM | ¥22,969.00MM |
| Investing Cash Flow | ¥-22,723.00MM | ¥-25,321.00MM | ¥-10,097.00MM |
| Financing Cash Flow | ¥-24,522.00MM | ¥-22,720.00MM | ¥-57,809.00MM |
| Earnings Per Share** | ¥193.31 | ¥147.86 | ¥163.76 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.